For example, IL-33 was found to increase antigen-specific CD8+ T cell responses and elicit effector-memory CD8+ T cells in a human papillomavirus-associated tumor model; it was therefore considered to be an immunoadjuvant in vaccinations against pathogens, including in antitumor immunotherapy 15. Here, CD8A is linked to neoplasm.